checkAd

     141  0 Kommentare Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis - Seite 3

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    Contact

    Wenyi Wei
    wwei@xbiotech.com
    Tel. 737-207-4600 


    1 Bunning et al. The effect of interleukin-1 on connective tissue metabolism and its relevance to arthritis Agents Actions Suppl. 1986:18:131-52.
    2 Vershure & Van Noorden. The effects of interleukin-1 on articular cartilage destruction as observed in arthritic diseases, and its therapeutic control. Clin Exp Rheumatol. 1990 May-Jun;8(3):303-13.


    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Verfasst von globenewswire
    Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis - Seite 3 (Phase II Multicenter Study is Proceeding Well with High Anticipation)AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) - XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research …